Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients. Results From the PREPARE (Primary Prevention Parameters Evaluation) Study

Journal of the American College of Cardiology

Volumn 52, Issue 7, 2008, Pages 541-550

  Wilkoff, Bruce L ^a   Williamson, Brian D ^b   Stern, Richard S ^c   Moore, Stephen L ^d   Lu, Fei ^e   Lee, Sung W ^f   Birgersdotter Green, Ulrika M ^g   Wathen, Mark S ^h   Van Gelder, Isabelle C ⁱ   Heubner, Brooke M ^j   Brown, Mark L ^j   Holloman, Keith K ^j  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c Doctors Medical Center   (United States)

^d EMH Regional Medical Center   (United States)

^e Regions Medical Center   (United States)

^f WASHINGTON ADVENTIST HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j MEDTRONIC INC   (United States)

more..

Author keywords

cardioversion; defibrillation; defibrillators; implantable; tachyarrhythmias

Indexed keywords

AGED; ARTICLE; CARDIAC PATIENT; CLINICAL TRIAL; COHORT ANALYSIS; CONVULSIVE THERAPY; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART PACING; HEART RATE; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUPRAVENTRICULAR TACHYCARDIA;

AGED; CASE-CONTROL STUDIES; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; INCIDENCE; MALE; PROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; SYNCOPE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 48449088263     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.05.011     Document Type: Article

References (22)

1. Moss A.J., Zareba W., Hall W.J., et al., Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
2. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
3. Sears S.F., Todaro J.F., Urizar G., et al. Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol 23 (2000) 939-945
4. Lüderitz B., Jung W., Deister A., Marneros A., and Manz M. Patient acceptance of the implantable cardioverter defibrillator in ventricular tachyarrhythmias. Pacing Clin Electrophysiol 16 (1993) 1815-1821
5. Mofrad P.S., Ottoboni L., Zei P.C., et al. VF and fatal cardiac arrest following ICD therapy delivery: what is the cause?. Pacing Clin Electrophysiol 30 (2007) 551-553
6. Wilkoff B.L., Hess M., Young J., and Abraham W.T. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 15 (2004) 1002-1009
7. Ousdigian K.T., Wilkoff B.L., Morgan J.M., et al. ICD patients with a history of spontaneous sustained VT have different outcomes than other secondary or primary prevention patients. Circulation 112 (2005) 17
8. Sweeney M.O., Wathen M.S., Volosin K., et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation 111 (2005) 2898-2905
9. Wathen M.S., DeGroot P.J., Sweeney M.O., et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock therapies (PainFREE Rx II) trial results. Circulation 110 (2004) 2591-2596
10. Wilkoff B.L., Ousdigian K.T., Sterns L.D., Wang Z.J., Wilson R.D., Morgan J.M., and EMPIRIC Trial Investigators. A comparison of EMpiric to Physician-tailored progRamming of Implantable Cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 48 (2006) 330-339
11. Wathen M.S., Sweeney M.O., DeGroot P.J., et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 104 (2001) 796-801
12. Schaumann A., von zur Muhlen F., Herse B., Gonska B.D., and Kreuzer H. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation 97 (1998) 66-74
13. Wilkoff B.L., Kuhlkamp V., Volosin K., et al. Critical analysis of dual-chamber implantable cardioverter-defibrillator arrhythmia detection: results and technical considerations. Circulation 103 (2001) 381-386
14. Gehi A.K., Mehta D., and Gomes J.A. Evaluation and management of patients after implantable cardioverter-defibrillator shock. JAMA 296 (2006) 2839-2847
15. Russo A.M., Nayak H., Verdino R., et al. Implantable cardioverter defibrillator events in patients with asymptomatic nonsustained ventricular tachycardia: is device implantation justified?. Pacing Clin Electrophysiol 26 (2003) 2289-2295
16. Wilkoff B.L., Stern R., Williamson B., et al. Design of the Primary Prevention Parameters Evaluation (PREPARE) trial of implantable cardioverter defibrillators to reduce patient morbidity. Trials 7 (2006) 18
17. Young J.B., Abraham W.T., Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA 289 (2003) 2685-2694
18. Liang K.Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
19. D'Agostino R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
20. Bansch D., Castrucce M., Bocker D., Breithardt G., and Block M. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 36 (2000) 557-565
21. Pinski S.L., and Fahy G.J. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 92 (1995) 1651-1664
22. Sweeney M.O., and Ruskin J.N. Mortality benefits and the implantable cardioverter-defibrillator. Circulation 89 (1994) 1851-1858